Fig 1.
Flow chart of case selection in this study.
The rheumatoid arthritis (RA) patients, and age- and sex-matched non-RA control subjects were selected from the Taiwan National Health Insurance research database (NHIRD).
Table 1.
Baseline characteristics and the occurrence of tuberculosis (TB) in rheumatoid arthritis (RA) patients and age- and gender-matched individuals from the general population 2001–2011 (n = 210,900).
Table 2.
Risk factors for developing TB adjusted by age at entry, sex, the use of corticosteroids, comorbidities and Charlson comorbidity index (CCI) in rheumatoid arthritis cohort.
Table 3.
Incidence rates (IRs) and hazard ratios (HRs) of tuberculosis (TB) disease by biologic exposure with csDMARDs-exposed patients as reference group, and by isoniazid prophylaxis therapy (INHP) with the absence of INHP as reference group.
Fig 2.
Cumulative incidence of tuberculosis in RA patients, who received therapy with csDMARDs, etanercept, adalimumab or rituximab, in comparison with non-RA subjects.
csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs.
Table 4.
Multivariable analysis for mortality after the diagnosis of tuberculosis (TB) in RA patients according to therapeutic agents and the risk factors of mortality.